Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study.
Somatrogon did not show a statistically significant difference in trunk fat mass change compared to placebo at 26 weeks, raising questions about its efficacy in adults with growth hormone deficiency.
Where it sits
this study against the rest of the hgh (somatropin) corpusSummary and findings
This study assessed the efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency (aGHD). A total of 202 patients were randomized, with 198 receiving treatment. The primary endpoint showed no significant difference in trunk fat mass change between somatrogon and placebo.
Abstract
PURPOSE: This study assessed the efficacy and safety of once-weekly somatrogon, a long-acting growth hormone, in adults with growth hormone deficiency (aGHD). METHODS: A phase 3 randomized, double-blind, placebo-controlled study consisted of a 26-week double-blind period (Period 1), a 26-week open-label extension (OLE; Period 2), and a multi-year OLE (Period 3). Patients were randomized 2:1 to somatrogon or placebo in Period 1, with dosing adjusted for gender, age, and estrogen therapy. All patients received somatrogon in Periods 2 and 3. Primary endpoint was change in trunk fat mass (FM; baseline-Week 26). Secondary endpoints included changes in total FM, lean body mass (LBM), percentage change in trunk FM, and trunk FM. Changes in percent trunk FM relative to total trunk mass (FM + LBM), trunk LBM, and appendicular skeletal muscle mass were also evaluated in a post-hoc supplemental analysis. Safety assessments included adverse events (AEs) and laboratory evaluations. RESULTS: Of 389 patients screened, 202 were randomized, and 198 received treatment (somatrogon:133; placebo:65). Mean IGF-I SDS normalized following somatrogon initiation. There was no significant difference between somatrogon and placebo in change in trunk FM from baseline to Week 26 (-0.37 vs 0.03 kg; p=0.0821; primary endpoint) or in total FM. However, somatrogon significantly improved LBM, trunk FM as a percentage of total FM and the three supplemental endpoints. AE incidence was similar between groups, with most being mild to moderate in severity. CONCLUSION: Somatrogon significantly improved several body composition parameters and was well tolerated overall in adults with GHD. CLINICALTRIALS.GOV: NCT01909479; registration date: 25/07/2013
Background
The paper addresses the clinical question of how effective and safe somatrogon is for treating adults with growth hormone deficiency. Prior studies have established the role of growth hormone in metabolic processes, but the specific efficacy of somatrogon compared to existing treatments is less well understood. This study is significant as it explores a new dosing regimen that may improve adherence and outcomes.
Methods
The study utilized a randomized controlled trial design, but specific details regarding the population size, dosing regimen, duration, and outcome measures were not reported in the abstract. The primary and secondary outcomes were likely related to growth hormone levels and safety assessments, but these specifics were not provided.
Results
Not reported in abstract.
Interpretation
Without specific results, it is difficult to compare the findings to existing literature or assess the clinical significance of the outcomes. The lack of reported effect sizes or p-values limits the ability to draw conclusions about the efficacy of somatrogon. Potential confounds include the absence of detailed methodology and results, which raises questions about the robustness of the findings.
Key findings
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.